Evidence map›Paper›PMID 38951840›Full record

ArticleBMC medical genomics2024

Analysis of molecular epidemiological characteristics and antimicrobial susceptibility of vancomycin-resistant and linezolid-resistant Enterococcus in China.

Ping Pan, Long Sun, Xinyan Shi, Xian Huang, Yiping Yin, Beilei Pan, Lihua Hu, Qiang Shen

Abstract read
In one paragraph

Article in BMC medical genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Genomic characterization of vancomycin-resistantFrontiers in microbiology · 2026
    Article
  6. Linezolid in the Focus of Antimicrobial Resistance ofInternational journal of molecular sciences · 2025
    Review
  7. Pathogens (Basel, Switzerland) · 2025
    Article
  8. Molecular Characterization of Linezolid-Non-SusceptibleInfection and drug resistance · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ping Pan *Department of Clinical Laboratory, Hangzhou Women's Hospital (Hangzhou Matenal and Child Health Care Hospital), Hangzhou, Zhejiang, 310000, China.
Long Sun *Department of Clinical Laboratory, Hangzhou Women's Hospital (Hangzhou Matenal and Child Health Care Hospital), Hangzhou, Zhejiang, 310000, China.
Xinyan ShiDepartment of Clinical Laboratory, Hangzhou Women's Hospital (Hangzhou Matenal and Child Health Care Hospital), Hangzhou, Zhejiang, 310000, China.
Xian HuangRespiratory department, Zhejiang Provincial General Hospital of Chinese People's Armed Police CN, Hangzhou, Zhejiang, 310051, China.
Yiping YinDepartment of Hospital-acquired infection control, Zhejiang Provincial General Hospital of Chinese People's Armed Police CN, Hangzhou, Zhejiang, 310051, China.
Beilei PanDepartment of Clinical Laboratory, Hangzhou Women's Hospital (Hangzhou Matenal and Child Health Care Hospital), Hangzhou, Zhejiang, 310000, China.
Lihua HuDepartment of Critical Care Medicine, Zhejiang Provincial General Hospital of Chinese People's Armed Police CN, Hangzhou, Zhejiang, 310051, China. hhx1819@sina.com.
Qiang ShenHangzhou xixi Hospital, Hangzhou, Zhejiang, 310023, China. shenq215@163.com.

Funding

Hangzhou agricultural and social development Scientific Research 20201203B151
6 · The paper itself

Abstract

backgroundThis study investigates the distribution and characteristics of linezolid and vancomycin susceptibilities among Enterococcus faecalis (E. faecalis) and Enterococcus faecium (E. faecium) and explores the underlying resistance mechanisms.

methodsA total of 2842 Enterococcus clinical isolates from patients were retrospectively collected, and their clinical data were further analyzed. The minimum inhibitory concentrations (MICs) of vancomycin and linezolid were validated by broth dilution method. The resistance genes optrA, cfr, vanA, vanB and vanM were investigated using polymerase chain reaction (PCR). Housekeeping genes and resistance genes were obtianed through whole-genome sequencing (WGS).

resultsOf the 2842 Enterococcus isolates, 88.5% (2516) originated from urine, with E. faecium accounted for 60.1% of these. The vanA gene was identified in 27/28 vancomycin resistant Enterococcus (VRE) isolates, 4 of which carried both vanA and vanM genes. The remaining strain was vanM positive. The optrA gene was identified in all E. faecalis isolates among linezolid resistant Enterococcus (LRE). E. faecium showed a higher multiple antibiotic resistance index (MAR index) compared to E. faecalis. The multi-locus sequence typing (MLST) showed the sequence type of E. faecium mainly belongs to clonal complex (CC) 17, nearly E. faecalis isolates analyzed were differentiated into 7 characteristics of sequence types (STs), among which ST16 of CC16 were the major lineage.

conclusionUrine was the primary source of VRE and LRE isolates in this study. E. faecium showed higher levels of resistance compared to E. faecalis. OptrA gene was detected in 91.6% of LRE, which could explain linezolid resistance, and van genes were detected in all vancomycin resistant Enterococcus strains, while vanA was a key resistance mechanism in VRE identified in this study.

Indexed as

Enterococcus faeciumGram-Positive Bacterial InfectionsLinezolidMicrobial Sensitivity TestsAdultAgedAnti-Bacterial AgentsChinaEnterococcusEnterococcus faecalisFemaleHumansMaleMiddle AgedMolecular EpidemiologyRetrospective StudiesAnti-Bacterial AgentsLinezolidVancomycinAntibiotic resistanceEnterococcus faecalisEnterococcus faeciumLinezolidVancomycin

Identifiers

PMID38951840
PMCPMC11218351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.